New blood pressure drug HJB647 enters first human tests
NCT ID NCT07644364
First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This early-stage study tests a new drug called HJB647 in Japanese adults with elevated blood pressure or mild-to-moderate hypertension. The main goal is to check safety and how the drug moves through the body. About 74 participants will receive either HJB647 or a placebo, with doses given once or multiple times.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HJB647 (oral capsule)
- What this could lead to
- If successful, this could lead to a new treatment option for high blood pressure.
- What could go wrong
- This is an early Phase 1 trial with only 74 participants, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED BLOOD PRESSURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGSumida Ku, Tokyo, 1300004, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?